← Search all jobs

Scientist I/II, In Vivo Pharmacology

world

New York, NY · $111k–$150k a year · Posted October 21, 2026

Just laid off? Start here: a plan for the first weeks

See every open role at world

More in New York job market · Healthcare & Hospital Systems · Clinical jobs

More roles at world

Similar jobs

Where New York, NY ranks

Where New York, NY placed in our monthly rankings, month by month. Each month stays online at its own address.

November 2026

Rankings about clinical jobs

Clinical jobs · Top Clinical employers · All rankings

Skills this job asks for

Say which you have and which you want to build. We use it to match you to jobs like this one.

About the job

Role Summary

Lexeo is seeking a hands-on in vivo pharmacologist to build rodent models of cardiac disease and use them to de-risk targets, screen therapeutic candidates and advance our discovery pipeline. The scientist will design, perform or manage rodent studies from target validation through hit identification, working cross-functionally with In Vitro Pharmacology, Modality Engineering, and Translational Sciences to select-advance molecules. Reporting to the Head of Cardiac Research, this role joins cardiac, neuroscience, and non-clinical scientists developing therapies for genetic heart disease and offers broad experience in multidisciplinary biopharma research.

Primary Responsibilities

Design and execute in vivo studies that de-risk novel targets, using genetic knockdown/overexpression and tool molecules to test target–phenotype links

Outsource or internally establish rodent cardiac disease models, including transgenic lines and surgical models such as TAC and MI

Run therapeutic screening studies that rank candidates on efficacy, dose-response, durability, and identify hit molecules for advancement

Dose by multiple routes (IV, IP, SC, IM, PO, retro-orbital) and by osmotic minipump across longitudinal studies

Lead study takedowns: necropsy, blood and tissue collection, and processing for histology, molecular, and ex vivo endpoints, including Langendorff cardiac dissociation

Partner with Translational Sciences to establish bioanalytical methods for biodistribution and target engagement in rodent tissues, and align on models with clinical endpoints/biomarkers

Analyze, interpret, and present data to project teams; keep study records in the ELN in line with IACUC and animal welfare standards

Manage study logistics, manage budgets, flag capacity or timeline risks early, and ideate novel methods for pharmacology and physiology

Required Skills and Qualifications

PhD in physiology, pharmacology, cardiovascular biology, or a related field with 0–3 years of postdoctoral or industry experience; or MS with 5+ years of industry experience

Hands-on rodent experience: handling, multi-route dosing, blood collection, survival surgery, and necropsy

Track record using rodent disease models for target validation or efficacy testing of molecules

Proven understanding of power analyses, methods of randomizing animal models and appropriate uses of statistical methods

Strong data analysis skills (e.g., GraphPad) and clear written and verbal communication

Organized and independent; able to run several longitudinal studies at once within a collaborative team

Ability to regularly work onsite at HQ in New York City

Preferred Skills and Qualifications

Industry experience in a small, fast-paced biotech is highly preferred

Working knowledge of qPCR/ddPCR for vector/mRNA, ELISA/LC-MS for ASO, RNAscope/IHC for tissue localization, WB/ ELISA/MSD for protein detection

Hands-on echocardiography in mice and rats (e.g., Vevo)

ECG and blood pressure telemetry implantation and analysis in mice and rats (e.g., Ponemah)

Cardiac surgical models (TAC, MI) and invasive hemodynamics (PV-loop)

Demonstrated experience with models of neurodegenerative disease, particularly ataxia or cerebellar disorders, including execution and interpretation of rotarod, gait analysis, balance beam, grip strength, and longitudinal behavioral studies

In vivo experience working with and advancing AAV or oligonucleotide therapeutics

Experience selecting and evaluating CROs to perform animal studies

AALAS certification or equivalent

About LEXEO

Lexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2) arrhythmogenic cardiomyopathy, and others in devastating diseases with high unmet need.

LEXEO Therapeutics is an EEO employer committed to an exciting, diverse, and enriching work environment.